ROM InWest Invests €5 Million in Dutch Microscopy Firm Confocal.nl
Amsterdam, Friday, 7 February 2025.
ROM InWest and Nascent Ventures have invested €5 million in Confocal.nl to enhance live-cell microscopy technology, aiming to expand the company’s international presence and technological reach.
Advanced Microscopy Innovation
Amsterdam-based Confocal.nl is revolutionizing the field of photonics through their development of sophisticated microscopes that enable scientists to study living cells more efficiently [1]. The company’s technology utilizes minimal laser light while maintaining high resolution, preventing cells from altered behavior, bleaching, or premature death [1]. This breakthrough allows researchers to conduct longer and more precise studies of cellular processes [1].
Healthcare Impact and Accessibility
According to Pim Vos, CEO of Confocal.nl, their innovation makes complex confocal microscopy more accessible to a broader scientific community [1]. This advancement is particularly crucial for research into new medications and treatments for complex diseases [1]. Janet Nieboer, CEO of ROM InWest, highlights the technology’s potential in fighting diseases like cancer, while simultaneously contributing to reduced healthcare costs [1].
Strategic Growth and Market Expansion
The €5 million investment will be utilized to automate Confocal.nl’s products and enhance their international market presence [1]. The company is specifically targeting expansion in Europe and the United States [1]. This strategic funding round includes support from established partners such as Rabobank Startup & Scale-up team, RVO Innovatiekrediet, VCC TechNanoFund, ECFG, University of Amsterdam Ventures, and Innovatiefonds Noord-Holland [1].
Regional Innovation Impact
This investment reinforces ROM InWest’s commitment to supporting innovative companies that contribute to a sustainable and social economy in North Holland [1]. The collaboration brings together various strategic partners, combining expertise from both academic and industrial sectors [1]. This partnership structure demonstrates the region’s strong support for advanced technological developments in the life sciences sector [GPT].